A Soluble Form of the Triggering Receptor Expressed on Myeloid Cells-1 Modulates the Inflammatory Response in Murine Sepsis
Top Cited Papers
Open Access
- 22 November 2004
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 200 (11) , 1419-1426
- https://doi.org/10.1084/jem.20040708
Abstract
The triggering receptor expressed on myeloid cells (TREM)-1 is a recently discovered receptor expressed on the surface of neutrophils and a subset of monocytes. Engagement of TREM-1 has been reported to trigger the synthesis of proinflammatory cytokines in the presence of microbial products. Previously, we have identified a soluble form of TREM-1 (sTREM-1) and observed significant levels in serum samples from septic shock patients but not controls. Here, we investigated its putative role in the modulation of inflammation during sepsis. We observed that sTREM-1 was secreted by monocytes activated in vitro by LPS and in the serum of animals involved in an experimental model of septic shock. Both in vitro and in vivo, a synthetic peptide mimicking a short highly conserved domain of sTREM-1 appeared to attenuate cytokine production by human monocytes and protect septic animals from hyper-responsiveness and death. This peptide seemed to be efficient not only in preventing but also in down-modulating the deleterious effects of proinflammatory cytokines. These data suggest that in vivo modulation of TREM-1 by sTREM peptide might be a suitable therapeutic tool for the treatment of sepsis.Keywords
This publication has 36 references indexed in Scilit:
- Mycobacterium bovisBCG Cell Wall-Specific Differentially Expressed Genes Identified by Differential Display and cDNA Subtraction in Human MacrophagesInfection and Immunity, 2004
- Crystal Structure of the Human Myeloid Cell Activating Receptor TREM-1Structure, 2003
- TREMs in the immune system and beyondNature Reviews Immunology, 2003
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003
- Clinical Trials of Immunomodulatory Therapies in Severe Sepsis and Septic ShockClinical Infectious Diseases, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Tumor Necrosis Factor-Dependent Adhesions as a Major Protective Mechanism Early in Septic Peritonitis in MiceInfection and Immunity, 2001
- Induction of Direct Antimicrobial Activity Through Mammalian Toll-Like ReceptorsScience, 2001
- Search for Sepsis Drugs Goes on Despite Past FailuresScience, 1994
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992